Skip to main content
Health Podcast Library
Episode 212

Apr 29, 2022 This Week in Cardiology Podcast

This Week in Cardiology · 22 min

Episode Description

Aspirin for primary prevention, time-restricted feeding, renal denervation, and a potential new obesity drug are the topics John Mandrola, MD, covers in this week's podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic

I – ASA for Primary Prevention:

- USPSTF Final Recommendation on Aspirin for Primary CV Prevention https://www.medscape.com/viewarticle/972761

- Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement https://jamanetwork.com/journals/jama/fullarticle/2791399

- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly https://www.nejm.org/doi/10.1056/NEJMoa1805819

- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly https://www.nejm.org/doi/full/10.1056/NEJMoa1803955

II – Time Restricted Feeding

- Is There a Benefit to Fasting Plus Calorie Counting? https://www.medscape.com/viewarticle/972579

- Calorie Restriction with or without Time-Restricted Eating in Weight Loss https://www.nejm.org/doi/full/10.1056/NEJMoa2114833

- Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. The TREAT Randomized Clinical Trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095

III – Renal Denervation

- Renal Denervation BP Benefits Remain at 3 Years: SPYRAL HTN-ON https://www.medscape.com/viewarticle/971883

- Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial https://doi.org/10.1016/S0140-6736(22)00455-X

IV – Tirzepatide for Obesity

- Tirzepatide Excites in Obesity Now Too, Says Lilly https://www.medscape.com/viewarticle/972936

- Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 https://www.prnewswire.com/news-releases/lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-surmount-1--301534871.html

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Proudly Supported by

BetterHelpForvis MazarsAAOSCalendarPAmowPod

Patrons of Health Podcast Library

AAOS Career Podcast
Achieving Health
AAOS Now Podcast
OrthoInfo
Stronger After Stroke
Who the Health Cares? with Prof Michael Sparer
Aging Like a Pro

Supporting Shows

This Just In Radio Show
Coffee Break: Breaking the Cycle of Bullying in Healthcare, One Cup at a Time
Coaching Healthcare Leaders
Faces of Digital Health
Cuts and Consults
Speak Up For Your Health
Impulse | Meeting Healthcare Pioneers
HIT Like a Girl Pod: Empowering Women in Health IT
On the Pulse Podcast
Hopeful Hints
Healthcare for Humans
HITea With Grace
Beyond Clinical Walls
Beyond The Paper Gown Podcast
Thriving with Addiction with Dr. Jonathan Avery
Nurse Rosa's INsights

We use cookies to run this site. Analytics cookies, which show us how it's used, stay off unless you accept them. Change your mind any time with the cookie button at the bottom right. How we use cookies